Upexi, Inc. (UPXI) carries very little sell-side coverage, and the two attributable targets that could be verified point in sharply different directions. Cantor Fitzgerald, with analyst Brett Knoblauch reiterating a Buy/Overweight rating, has maintained a $2.00 price target as recently as September 2026. Alliance Global Partners holds a Buy rating but cut its target from $15.00 to $8.00 in January 2026.
The arithmetic mean of these two figures is $5.00, with a low-to-high range of $2.00 to $8.00. That unusually wide spread — a fourfold difference — signals that analysts are not looking at the same near-term scenario. The higher target appears to give more weight to the value of the company's cryptocurrency holdings and a normalized capital structure, while the lower target is more conservative about execution and dilution. With only two firms contributing, this average should be read as a rough reference point rather than a tightly defined consensus, and it is not an official published consensus figure.
Upexi is a small, loss-making consumer products and digital assets company based in Tampa, Florida. It sells wellness, pet care, and functional supplement brands — including LuckyTail, PRAX, and Cure Mushrooms — through direct-to-consumer and e-commerce channels, and it has increasingly allocated its balance sheet toward Solana (SOL). The stock recently traded near $0.66, near the low end of its 52-week range of $0.54 to $3.65, with a market capitalization of roughly $58 million.
Moving from about $0.66 to $5.00 requires a gain of roughly 650%, which is a very large move by any standard. The path would likely depend less on the core consumer business and more on a re-rating of the Solana treasury, a successful resolution of the Nasdaq compliance issues, and a credible plan to reverse sustained losses. A reverse stock split, if approved, could mechanically raise the per-share price but would not by itself create shareholder value, so any analysis of a dollar target must consider whether it is measured on a pre- or post-split basis.
The most direct potential catalyst is the company's Solana exposure. Upexi has issued convertible notes to acquire SOL, effectively making it a leveraged proxy for the cryptocurrency's price. A sustained rally in Solana would strengthen the company's balance sheet and could support a meaningfully higher valuation. In addition, Cantor Fitzgerald's reiterated Overweight rating and $2.00 target represent one firm's view that the shares are undervalued relative to their assets and optionality.
Regaining Nasdaq compliance — including lifting the bid price back above $1.00 and securing shareholder approval for the contested note issuances — would remove a major overhang and could improve investor sentiment. The company's addition to the Russell Microcap Index in June 2026 also provided a degree of passive-index visibility, though it is not itself a driver of fundamental value.
The risks are substantial. Nasdaq notified Upexi that its shares closed below the $1.00 minimum bid price for 30 consecutive business days, and the company has until January 26, 2027, to regain compliance — potentially through a reverse stock split in the range of 1-for-2 to 1-for-4, which shareholders were scheduled to consider at a special meeting in November 2026. Separately, Nasdaq determined that the company's convertible note issuances for Solana violated shareholder-approval rules, another unresolved compliance matter.
Fundamentals are weak, with diluted EPS (earnings per share) over the trailing twelve months around negative $3.87 and a substantial net loss. The company's reliance on volatile cryptocurrency prices, combined with potential further share dilution from the convertible notes, adds material uncertainty. Solana's own price swings could weigh on the balance sheet just as easily as they could lift it, and any failure to resolve listing issues could force a move to a less liquid venue.
The shares have already given up most of their prior gains, having fallen from a 52-week high near $3.65 to a recent level under $0.70. The $1.00 mark now functions as both a regulatory threshold and a psychological resistance level, since the company must hold a closing bid at or above it for at least ten consecutive business days to satisfy Nasdaq's bid price rule. The $0.54 area represents the durable support zone from the 52-week low, while any move back toward $1.00 would first need to reclaim levels near the prior trading band around $1.00 to $1.50 that the stock held earlier in the year.
Analyst price targets generally reflect a research horizon of roughly 12 months, though the wide gap between the $2.00 and $8.00 targets shows that the two firms are effectively pricing different scenarios over different timelines. Key items to watch include the outcome of the shareholder vote on the reverse stock split and note approvals, Nasdaq's response to Upexi's compliance plan, the company's quarterly earnings and cash-burn trajectory, and the price of Solana. Any analyst target revisions or rating changes would also be significant given how thin the coverage is.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. These signals are designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone would allow. For a low-priced, high-volatility name such as Upexi, objective signal-based tools can add a useful layer of discipline to the decision-making process.
The $5.00 central target for Upexi is the average of just two widely divergent analyst targets — $2.00 from Cantor Fitzgerald and $8.00 from Alliance Global Partners — and it implies a gain of roughly 650% from a recent price near $0.66. That is a very large move, and the thin coverage and fourfold target range underscore how much uncertainty surrounds the stock. The upside case rests heavily on Solana appreciation, a repaired capital structure, and restored Nasdaq compliance, while the downside case is framed by listing deficiencies, heavy losses, and potential dilution. Because the gap between the two analyst views is so wide, the mean is best treated as a conceptual midpoint rather than a likely destination. Investors should focus next on the reverse stock split vote, Nasdaq's compliance decisions, quarterly results, and Solana's price action.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, UPXI has been loosely correlated with RUM. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if UPXI jumps, then RUM could also see price increases.
| Ticker / NAME | Correlation To UPXI | 1D Price Change % | ||
|---|---|---|---|---|
| UPXI | 100% | +3.83% | ||
| RUM - UPXI | 43% Loosely correlated | +3.36% | ||
| DJT - UPXI | 39% Loosely correlated | +1.75% | ||
| NBIS - UPXI | 34% Loosely correlated | +9.24% | ||
| SNAP - UPXI | 33% Poorly correlated | +1.81% | ||
| DJTWW - UPXI | 30% Poorly correlated | N/A | ||
More | ||||
| Ticker / NAME | Correlation To UPXI | 1D Price Change % |
|---|---|---|
| UPXI | 100% | +3.83% |
| Technology Services category (396 stocks) | 6% Poorly correlated | -0.87% |